New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (₩5.4b revenue, or US$3.6m). Market cap is less than US$100m (₩80.7b market cap, or US$53.7m). New Risk • Apr 04
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m). Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years. Annonce • Mar 17
INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026 INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years. New Risk • Jan 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m). Reported Earnings • Nov 19
Third quarter 2025 earnings released Third quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩11,270, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 73% over the past three years. Valuation Update With 7 Day Price Move • May 21
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩12,380, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 72% over the past three years. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to ₩12,620, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩5,980, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 7x in the Luxury industry in South Korea. Total loss to shareholders of 89% over the past three years. Annonce • Mar 13
INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025 INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea New Risk • Jan 15
New major risk - Revenue and earnings growth Earnings have declined by 1.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 1.9% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.4b revenue, or US$4.4m). Market cap is less than US$100m (₩66.8b market cap, or US$45.8m). Board Change • Jan 13
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annonce • Aug 09
INBIOGEN Co., Ltd. announced that it expects to receive KRW 30.00000036 billion in funding INBIOGEN CO.,Ltd announced a private placement of 15,957,447 convertible preferred shares at KRW 1,880 per share for gross proceeds of KRW 30,000,000,360 on August 8, 2022. The transaction will include participation from new investor Scan No. 1 Association. The transaction is by way of third party capital increase. The payment date for the shares is expected on October 28, 2022. The transaction has been approved by board of directors of the company. The preferred shares are registered and 100% convertible from October 29, 2023 - September 29, 2032. The convertible preferred shares are issued at 10% discount. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 16% share price gain to ₩1,830, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 50% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 20% share price decline to ₩1,835, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 59% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annonce • Sep 01
INBIOGEN CO.,Ltd announced that it has received KRW 15 billion in funding On August 31, 2021, INBIOGEN CO.,Ltd closed the transaction. The company issued KRW 15,000,000,000 in the transaction. Annonce • Jun 01
INBIOGEN CO.,Ltd announced that it has received KRW 23.300002 billion in funding from Bucket Studio Co., Ltd. On May 31, 2021, INBIOGEN CO.,Ltd (KOSE:A101140) closed the transaction. Annonce • Mar 18
INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021 INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021, at 10:30 Korea Standard Time. Is New 90 Day High Low • Feb 18
New 90-day low: ₩3,580 The company is down 48% from its price of ₩6,860 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 31
New 90-day low: ₩3,600 The company is down 46% from its price of ₩6,680 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period. Annonce • Dec 04
BTONE CO.,Ltd announced that it expects to receive KRW 25.00000128 billion in funding BTONE CO.,Ltd (KOSE:A101140) announced a private placement of 4,340,278 registered convertible preferred stock at an issue price of KRW 5,760 per share for gross proceeds of KRW 25,000,001,280 on December 2, 2020. The transaction will include participation from JJ Fund. The company will raise funding through third party allotment. The preferred stock will be fully convertible into the 4,340,278 registered common stock of the company at a conversion price of KRW 5,760 per share. The conversion period of the preferred stock will be from February 19, 2022 to January 19, 2031. The preferred stock will be issued at discount of 10%. The transaction is expected to close on February 19, 2021 and expected date of issuance of new shares is March 05, 2021. The security issued in the transaction will be subject to hold period of one year. The transaction was approved by the board of directors of the company. Annonce • Nov 26
BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in funding BTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 7 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on November 25, 2020. The transaction will include participation from JJ 1 Fund. The bonds will mature on January 29, 2024 and will carry 1% interest coupon and 2% yield to maturity. The bonds will be fully convertible into the 2,762,812 registered common stock of the company at a conversion price of KRW 7,239 per share. The conversion period of the bonds will be from January 29, 2022 to December 29, 2023. The bonds will be issued at its par value. The transaction is expected to close on January 29, 2021 and subscription date is November 27, 2020. The transaction was approved by the board of directors of the company. Is New 90 Day High Low • Nov 04
New 90-day high: ₩7,290 The company is up 87% from its price of ₩3,900 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 10.0% over the same period. Is New 90 Day High Low • Oct 19
New 90-day high: ₩4,570 The company is up 25% from its price of ₩3,650 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 7.0% over the same period. Annonce • Oct 17
BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in funding BTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 6 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on October 16, 2020. The transaction will include participation from Hoyeon 3 Fund. The bonds will mature on November 30, 2023 and will not carry 1% interest coupon and 2% yield to maturity. The bonds will carry lump sum redemption on its maturity. The bonds will be fully convertible into the 5,357,621 registered common stock of the company at a conversion price of KRW 3,733 per share for 12.75% stakes in the company. The conversion period of the bonds will be from November 30, 2021 to October 30, 2023. The bonds will be issued at its par value. The transaction is expected to close on November 30, 2020 and subscription date will be October 21, 2020. The transaction was approved by the board of directors of the company.